Clinical Scorecard: Differences in Placental Immunology Associated with HIV: Insights from the PRACHITi Cohort in Pune, India
At a Glance
Category
Detail
Condition
Maternal HIV infection and its impact on placental immunology
Key Mechanisms
Altered placental FcRn expression and increased placental CD8+ T-cell abundance affecting transplacental antibody transfer
Target Population
Pregnant women living with HIV and their infants
Care Setting
Obstetric and infectious disease care settings in resource-limited environments
Key Highlights
Women living with HIV have significantly lower placental FcRn expression compared to women without HIV, regardless of viral suppression status.
Placental CD8+ T-cell abundance is increased in women with HIV, independent of viral load suppression.
Maternal HIV-associated placental immune dysregulation persists despite antiretroviral therapy and may contribute to poorer infant outcomes in HIV-exposed uninfected infants.
Guideline-Based Recommendations
Diagnosis
Screen pregnant women for HIV and monitor CD4 counts and viral load during pregnancy and delivery.
Assess placental inflammation and FcRn expression in research settings to understand immune alterations.
Management
Administer combined antiretroviral therapy to pregnant women living with HIV to achieve viral suppression.
Monitor infants exposed to HIV for increased risk of infections despite absence of HIV transmission.
Monitoring & Follow-up
Regularly monitor maternal CD4 counts and viral load at entry, delivery, and postpartum.
Test infants of women living with HIV for HIV infection at birth, 6 weeks, 6 months, and 18 months.
Risks
Persistent placental immune dysregulation despite viral suppression may increase risk of infection-related morbidity in HIV-exposed uninfected infants.
Pregnant women living with HIV on combined antiretroviral therapy
Despite effective ART and viral suppression, placental immune alterations persist, indicating a need for enhanced monitoring and supportive care for infants.
Clinical Best Practices
Ensure early initiation and adherence to combined antiretroviral therapy during pregnancy.
Conduct comprehensive maternal and infant follow-up to detect and manage immune-related complications.
Consider research into adjunctive therapies to address placental immune dysregulation in HIV-positive pregnancies.
by Jyoti S Mathad, Mallika Alexander, Ramesh Bhosale, Shilpa Naik, Lisa Marie Cranmer, Vandana Kulkarni, Sydney Busch, Andrea Chalem, Emily Gitlin, Jun Lei, Anguo Liu, Jin Liu, Yang Liu, Rupak Shivakoti, Amita Gupta, Irina Burd
